ATE408413T1 - Pralmorelin-haltige nasentropfen-präparate - Google Patents

Pralmorelin-haltige nasentropfen-präparate

Info

Publication number
ATE408413T1
ATE408413T1 AT01932322T AT01932322T ATE408413T1 AT E408413 T1 ATE408413 T1 AT E408413T1 AT 01932322 T AT01932322 T AT 01932322T AT 01932322 T AT01932322 T AT 01932322T AT E408413 T1 ATE408413 T1 AT E408413T1
Authority
AT
Austria
Prior art keywords
pralmorelin
alanyl
preparation
preparations containing
nose drop
Prior art date
Application number
AT01932322T
Other languages
English (en)
Inventor
Akiko Ochiai
Yasutomi Kato
Hirokuni Kogetsu
Kiyoshi Maruyama
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of ATE408413T1 publication Critical patent/ATE408413T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
AT01932322T 2000-05-29 2001-05-29 Pralmorelin-haltige nasentropfen-präparate ATE408413T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000158676A JP3498041B2 (ja) 2000-05-29 2000-05-29 プラルモレリン含有点鼻用製剤

Publications (1)

Publication Number Publication Date
ATE408413T1 true ATE408413T1 (de) 2008-10-15

Family

ID=18663108

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932322T ATE408413T1 (de) 2000-05-29 2001-05-29 Pralmorelin-haltige nasentropfen-präparate

Country Status (7)

Country Link
US (1) US7008927B2 (de)
EP (1) EP1297838B1 (de)
JP (1) JP3498041B2 (de)
AT (1) ATE408413T1 (de)
AU (1) AU2001258859A1 (de)
DE (1) DE60135845D1 (de)
WO (1) WO2001091782A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
JP4584331B2 (ja) * 2005-03-11 2010-11-17 インデバス ファーマシューティカルズ、インク． オクトレオチドの放出制御製剤
WO2008082885A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
WO2009158415A1 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
WO2009158412A2 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080879B1 (de) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
JPS63303931A (ja) 1987-06-05 1988-12-12 Sumitomo Pharmaceut Co Ltd 経鼻投与用成長ホルモン放出活性物質製剤
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
CA2174324A1 (en) * 1993-10-21 1995-04-27 Katsuya Mukae Pernasal composition and pernasal preparation containing the same
JP2660484B2 (ja) * 1994-04-12 1997-10-08 株式会社ミドリ十字 ヒト尿性トリプシンインヒビター含有液状製剤
JPH1045619A (ja) * 1996-07-31 1998-02-17 Kaken Pharmaceut Co Ltd 成長ホルモン分泌促進ペプチド含有経口製剤
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
CA2413252A1 (en) * 2000-06-23 2002-12-20 Takahiko Murata Preventives or remedies for heart failure
JP2002053489A (ja) * 2000-08-07 2002-02-19 Kaken Pharmaceut Co Ltd 筋肉増強剤・筋肉減衰の予防・治療剤

Also Published As

Publication number Publication date
US7008927B2 (en) 2006-03-07
JP2001335508A (ja) 2001-12-04
AU2001258859A1 (en) 2001-12-11
EP1297838A1 (de) 2003-04-02
EP1297838B1 (de) 2008-09-17
US20030139347A1 (en) 2003-07-24
WO2001091782A1 (fr) 2001-12-06
EP1297838A4 (de) 2003-07-09
JP3498041B2 (ja) 2004-02-16
DE60135845D1 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
DK1091729T3 (da) Mikropartikelformulering til inhalation
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
ITMI912024A1 (it) Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
UY27320A1 (es) Nuevas composiciones farmacéuticas
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
HRP20020404B1 (en) Solutions containing epinastine
PT96506A (pt) Processo para a preparacao de composicoes orais que incorporam como ingrediente activo pimobendano
NO20023875D0 (no) Stabilt nasalt, oralt eller sublingualt anvendbart preparat
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
SE0002476D0 (sv) New compounds
ATE408413T1 (de) Pralmorelin-haltige nasentropfen-präparate
NO912414L (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
EP0647616A4 (de) Zink-tranexamat derivat.
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
DK1220678T3 (da) Farmaceutiske præparater indeholdende kobber, salicylsyre og C-vitamin
SE8101374L (sv) Kompositioner innehallande n,n-dietyl-m-toluamid
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
GT199900171A (es) Concentrado oral de sertralina.
NO20013605D0 (no) Preparat for vorter
WO2000026185A3 (en) Omeprazole solution and method of using same
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
BR0108727A (pt) Composição micelar para o tratamento de doenças parasìticas em animais, e, uso de uma composição
WO2001045727A3 (en) Stabilized veterinary compositions comprising more than one antiviral agent

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee